Burkhart Craig N, Burkhart Craig G
Department of Internal Medicine, Brown University Medical School, Providence, RI, USA.
Int J Dermatol. 2004 Mar;43(3):215-9. doi: 10.1111/j.1365-4632.2004.02118.x.
There is clinical uncertainty concerning the effectiveness of the new topical immunomodulators vs. the conventional use of topical steroids for the treatment of atopic dermatitis.
To assess patient satisfaction with these two prescription topical remedies for atopic eczema.
In an open-label, 2-week, comparative study, 10 patients demonstrating atopiform dermatitis were given tacrolimus and 0.1% hydrocortisone butyrate in a 70% oil-in-water base to apply to the eczema on opposite sides of the body. After 2 weeks of applying the agents twice daily to their respective sides of the body surface, the study subjects completed a 12-question survey to assess their opinions of the two products.
There was a preference for the nonfluorinated topical steroid over tacrolimus in this cursory head-to-head study. There were no withdrawals from the study or side-effects reported with either product.
Trials of short duration with small numbers of patients do not adequately inform practitioners regarding the use of these topical remedies. However, the higher satisfaction of patients with 0.1% hydrocortisone butyrate in a 70% oil-in-water base over tacrolimus certainly warrants further investigation.
对于新型局部免疫调节剂与传统局部使用类固醇治疗特应性皮炎的有效性，临床上存在不确定性。
评估患者对这两种用于治疗特应性湿疹的处方局部用药的满意度。
在一项为期2周的开放标签对比研究中，10名患有类特应性皮炎的患者分别使用他克莫司和70%水包油基质的0.1%丁酸氢化可的松，涂抹于身体两侧的湿疹处。在每天两次将药物涂抹于身体各自部位两周后，研究对象完成了一项包含12个问题的调查，以评估他们对这两种产品的看法。
在这项粗略的直接对比研究中，患者更倾向于使用非氟化局部类固醇而非他克莫司。两种产品均未出现退出研究的情况或报告有副作用。
小规模患者的短期试验不足以让从业者充分了解这些局部用药的使用情况。然而，70%水包油基质的0.1%丁酸氢化可的松比他克莫司更让患者满意，这无疑值得进一步研究。
